In a phase 2b clinical trial, an investigational oral therapy called PrimeC was found to be safe and well tolerated in people living with amyotrophic lateral sclerosis (ALS), with exploratory findings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results